NEW YORK, July 26, 2026, 14:22 EDT — With U.S. markets now closed, SELLAS Life Sciences stock ended down 14% as investors grew cautious waiting for updates on the REGAL program, testing the company’s $2.2 billion market value.
SELLAS Life Sciences Group NASDAQ:SLS closed at $11.32 on Friday, falling 8.3%. Over the past week, the stock declined 14.2%, compared with a 2.1% drop in the Nasdaq Composite.
Despite the decline, the stock maintains a significant clinical premium. Based on the June 2 share count, SELLAS held an equity value of around $2.23 billion.
Friday’s disclosures from the market and company reports yield this overview. The valuation multiples are early estimates based on the released numbers.
Measure
Latest reading
Comparison
SELLAS weekly change
-14.2%
Nasdaq Composite: -2.1%
Friday’s closing price
$11.32
Down 8.3% for the day
Market capitalisation
About $2.23 billion
Calculated from 196.63 million shares
Liquidity indicator
$135.8 million
6.1% of market cap
Preliminary value over liquidity
About $2.09 billion
93.9% of market cap
REGAL event tally
78 out of 80
Official total as of May 11
The rough estimate is significant as liquidity accounts for just 6.1% of equity value. The $2.09 billion figure results from deducting that proxy. This is not an official valuation or present-day enterprise value.
REGAL, a Phase 3 randomised trial evaluating galinpepimut-S in acute myeloid leukemia, will proceed to final analysis after the 80th death is reported. SELLAS stated that as of May 11, 78 such events had been recorded and the study remained blinded.
The distinction holds significance for investors. A pooled event rate showing slower results may derive from either treatment arm and does not represent efficacy data at the individual arm level.
Chief Executive Angelos Stergiou described the upcoming results as “an important milestone” in May. Hitting the threshold of 80 events will trigger database lock, followed by review, analysis, and unblinding. Sellas Life Sciences
Stergiou was featured on Fox & Friends on Friday during a four-minute segment highlighting AI in precision medicine. He stated that AI has the potential to “speed up the development work,” but did not specify any REGAL date. Fox News
New financing improved the balance sheet, while also increasing the equity base. The number of shares outstanding grew by 8.4% from March 31 to June 2. SELLAS maintained access to a $150 million at-the-market facility, which had not been used as of May 12.
SLS009 provides another potential milestone. SELLAS is conducting an 80-patient Phase 2 trial in patients newly diagnosed with AML. Initial results are anticipated in the fourth quarter of 2026.
The primary catalyst for July 27-31 is undated. SELLAS has stated it will disclose the 80th event upon its occurrence. Database lock and blinded review will then come before topline results.
Risks: REGAL may fail to reach its survival goal. The event date could be delayed compared to investor expectations. Additional warrant exercises or ATM offerings might result in dilution for shareholders, and SLS009 is still undergoing clinical trials.
By the end of trading on Friday, investors were primarily valuing the prospect of a successful REGAL result and future pipeline potential, rather than just the company’s cash. As a result, official updates from clinical trials continue to drive the stock’s movements.
What caused SELLAS shares to drop significantly on Friday?
SLS ended trading on Friday, July 24, at $11.32, marking an 8.27% decrease. Trading volume reached 6.73 million shares, which was below the 65-day average volume of 9.28 million shares. Over the week’s five sessions, the stock fell 9.26%. SELLAS did not release any press statement clarifying Friday’s drop. Pre-readout positioning might be a factor, but the specific reason is still uncertain.
Has the REGAL study observed its 80th death event yet?
There are 78 confirmed deaths, unchanged as of May 11. SELLAS stated it would make an announcement upon confirmation of the 80th event. By July 26, no such announcement had been made. This does not necessarily indicate the event has not taken place. Reporting and reconciliation on the site may cause delays.
What does REGAL need to demonstrate in order to be considered statistically successful?
The main goal for REGAL is overall survival following a second remission from AML. The final results are based on 80 deaths across the two randomized treatment arms. SELLAS stated that statistical significance would be reached with a hazard ratio of about 0.636. This represents 12.6 months compared to eight months median survival. This comparison is based on statistical design, not a projection.
Has REGAL’s interim analysis already demonstrated that GPS is effective?
No. The monitoring committee reported GPS did not cross the preset futility boundary. It also found no safety issues and advised the trial continue as planned. At the January 2025 assessment, pooled, blinded median survival was above 13.5 months. Additionally, 80% of randomly tested GPS recipients mounted a specific T-cell response. These updates do not substitute for the final comparative analysis of treatment arms.
How is the market valuing it ahead of REGAL data?
With shares priced at $11.32, SELLAS’s implied market capitalization stood at about $2.23 billion, based on the 196.63 million shares count as of June 2. SELLAS does not have any marketed products that produce commercial revenue. The firm posted a net loss of $8.4 million for the first quarter. As a result, its valuation is primarily tied to progress with GPS and SLS009.
Does SELLAS possess sufficient cash to sidestep immediate financing needs?
Cash and equivalents stood at $107.1 million as of March 31. Warrant exercises contributed roughly $28.7 million in April and May, resulting in $135.8 million prior to further operational expenses. The company used $8.8 million in operating cash during the first quarter. Management reported that current funding would last for at least twelve months starting May 12. The present cash balance has not been disclosed, and spending could rise following the readout.
What is the current extent of dilution risk?
Outstanding shares climbed from 186.03 million to 196.63 million as of June 2, marking a 5.7% rise over approximately three weeks. As of March 31, about 30.3 million warrants were still outstanding. Many of these were exercised later, though the updated remaining count has not been revealed. SELLAS also has access to a $150 million at-the-market equity facility. No ATM shares had been issued by the time of the May 12 filing.
In what ways might SLS009 add value outside of the GPS program?
The most recent relapsed AML dataset involved 35 patients considered evaluable. SLS009 combined with azacitidine and venetoclax yielded an overall response rate of 46%. Complete remission or CRi was seen in 29% of the patients. Participants who had received just one prior line of therapy achieved a 58% response rate. The trial size was limited and featured no randomized control arm. A first-line study with 80 patients aims for topline data readout in the fourth quarter of 2026.
What is the level of crowding in SLS short positions?
Short interest recorded on July 15 reached 55.28 million shares, reflecting a 12.7% decline from the level reported on June 30. According to data providers, the current short interest is estimated at between 28% and 30% of float. Analysts estimate the time required to cover these positions at about five to six trading days, suggesting trial news could significantly amplify share moves either way. The upcoming official settlement date is July 31, with data to be published August 11.
Which unexpected events might impact SLS in the next week?
Confirmation of REGAL’s 80th death event continues to be the most explicit catalyst. A ruling in SELLAS’ arbitration with 3D Medicines could also be imminent. The disputed development milestones amount to $13 million, with SELLAS seeking additional damages. The arbitration hearing concluded in January, but no timeline for a decision was given. SELLAS has not listed any scheduled investor events for July 27–31. Both potential events are legitimate, though their exact timing remains uncertain.
Khadija Saeed is a financial markets reporter at TS2.tech. Her coverage ranges from stocks and technology to emerging industries and developments across global markets. She studied economics and finance at the London School of Economics and worked in market research before becoming a financial journalist. Follow Khadija Saeed on Google News.
